There's a protein in people's and mice's joint tissues that might be a good target for treating arthritis.

12

Pro

0

Against

Evidence from Studies

Supporting (1)

12

Community contributions welcome

12

Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis

Cross-Sectional Study

Animal

2022 Jan 28

The study tests a drug that targets the GLP-1 receptor and finds it helps reduce joint pain and inflammation in mice, which suggests the receptor must be present and active in joint tissues. This supports the idea that the GLP-1 receptor could be a target for treating osteoarthritis.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Liraglutide, a glucagon-like peptide 1 receptor agonist, exerts analgesic, anti-inflammatory and anti-degradative actions in osteoarthritis

Score: 12

DOI: 10.1038/s41598-022-05323-7

Similar Assertions

Taking GLP-1 drugs might help rebuild and protect knee cartilage in people with arthritis.

34

0

83%

These diabetes-like drugs might help ease joint pain and slow down damage in arthritis by reducing pain, swelling, and joint breakdown.

12

0

82%

A type of diabetes drug might help protect joint cartilage in arthritis by stopping cells from leaking important building blocks.

12

0

82%

Some diabetes drugs might help people with knee or joint pain from osteoarthritis feel better and move easier, especially if they also have type 2 diabetes or are overweight.

1

0

81%

Those diabetes weight-loss drugs might help knee arthritis, but it's probably because people lose weight — not because the drug calms inflammation in the joint itself.

48

0

81%